Anal Cancer News and Research RSS Feed - Anal Cancer News and Research

Anal cancer is a type of cancer which arises from the anus, the distal orifice of the gastrointestinal tract. It is a distinct entity from the more common colorectal cancer.

Research team to investigate ways to develop novel immune therapies for HPV-associated cancers

Stand Up To Cancer and the Farrah Fawcett Foundation, along with the American Association for Cancer Research, SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9. [More]

SU2C and Farrah Fawcett announce formation of research team dedicated to HPV-related cancers

Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation, along with the American Association for Cancer Research (AACR), SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9. [More]
Japanese mushroom extract active hexose correlated compound (AHCC) may have role in prevention HPV-related cancers

Japanese mushroom extract active hexose correlated compound (AHCC) may have role in prevention HPV-related cancers

... [More]
First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors. [More]
Older HIV-positive men at higher risk of HPV that causes anal cancer

Older HIV-positive men at higher risk of HPV that causes anal cancer

Human papillomavirus, or HPV, which can cause cervical cancer in women, is also known to cause anal cancer in both women and men. Now, a study led by researchers at the UCLA School of Nursing has found that older HIV-positive men who have sex with men are at higher risk of becoming infected with the HPVs that most often cause anal cancer. [More]

Philadelphia hospital reaches out to homeless

The program helps reinforce the importance of health care for shelter residents and their children. [More]
HPV vaccine coverage among teens still remains low than other recommended vaccinations

HPV vaccine coverage among teens still remains low than other recommended vaccinations

Barriers to human papillomavirus (HPV) vaccination among adolescents in the U.S. range from financial concerns and parental attitudes to social influences and concerns about the vaccination's effect on sexual behavior, according to a review of the available medical literature published by JAMA Pediatrics, a JAMA Network publication. [More]

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV. [More]

Research reveals that HPV infection is associated with higher subsequent risk of HIV infection

A study of 2,519 Kenyan men conducted by researchers at the University of North Carolina revealed that infection with the human papillomavirus (HPV) was associated with a higher subsequent risk of infection with HIV, a precursor to AIDS. [More]

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia. [More]

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

Advaxis, Inc., (OTCQB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated anal cancer. [More]
p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer. [More]
Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Boys are more likely to receive the quadrivalent human papillomavirus vaccine if their mothers receive flu shots or Pap screenings, according to a Kaiser Permanente study published in the American Journal of Public Health. [More]

Scientists find high prevalence of HPV infection in oral, anal and penile cavities in HIV-positive men

Scientists in Barcelona have found a high presence of papillomavirus infection in oral, anal and penile cavities in HIV-positive men, particularly in the anal cavities of men who have homosexual sex. The researchers recommend routine examination of the three areas in all men, independently of their sexual behaviour. [More]
Sentinel lymph node biopsy for early breast cancer: an interview with Prof. Gordon Wishart, Anglia Ruskin University

Sentinel lymph node biopsy for early breast cancer: an interview with Prof. Gordon Wishart, Anglia Ruskin University

Our current method, which is recommended by the Association of Breast Surgeons in the UK, involves the use of injections of blue dye and radioisotope to identify the first node(s) under the arm (axilla) called the sentinel nodes. [More]

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer. [More]

Cleveland Clinic receives $2M for research in colorectal surgery

Kenneth M. Garschina and his wife, Sara Story, have pledged $2 million to Cleveland Clinic's Digestive Disease Institute to create an endowed chair for research in colorectal surgery. The donation coincides with the re-dedication of two previously funded endowed chairs. [More]

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG). [More]
Advaxis to license its ADXS-HPV product candidate to FusionVax

Advaxis to license its ADXS-HPV product candidate to FusionVax

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. ("FusionVax") setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia. [More]
BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting. [More]